As illustrated in Fig. 1A, KAT2A exhibited significantly higher expression in various tumors, including bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), and other malignancies. This evidence concerns the gene KAT2A and bladder transitional cell carcinoma.